BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 27209355)

  • 21. Genetic analyses of apparently sporadic pheochromocytomas: the Rotterdam experience.
    Korpershoek E; Van Nederveen FH; Dannenberg H; Petri BJ; Komminoth P; Perren A; Lenders JW; Verhofstad AA; De Herder WW; De Krijger RR; Dinjens WN
    Ann N Y Acad Sci; 2006 Aug; 1073():138-48. PubMed ID: 17102080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SDHB loss predicts malignancy in pheochromocytomas/sympathethic paragangliomas, but not through hypoxia signalling.
    Blank A; Schmitt AM; Korpershoek E; van Nederveen F; Rudolph T; Weber N; Strebel RT; de Krijger R; Komminoth P; Perren A
    Endocr Relat Cancer; 2010 Dec; 17(4):919-28. PubMed ID: 20702724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.
    Marinoni I; Kurrer AS; Vassella E; Dettmer M; Rudolph T; Banz V; Hunger F; Pasquinelli S; Speel EJ; Perren A
    Gastroenterology; 2014 Feb; 146(2):453-60.e5. PubMed ID: 24148618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma.
    Burnichon N; Cascón A; Schiavi F; Morales NP; Comino-Méndez I; Abermil N; Inglada-Pérez L; de Cubas AA; Amar L; Barontini M; de Quirós SB; Bertherat J; Bignon YJ; Blok MJ; Bobisse S; Borrego S; Castellano M; Chanson P; Chiara MD; Corssmit EP; Giacchè M; de Krijger RR; Ercolino T; Girerd X; Gómez-García EB; Gómez-Graña A; Guilhem I; Hes FJ; Honrado E; Korpershoek E; Lenders JW; Letón R; Mensenkamp AR; Merlo A; Mori L; Murat A; Pierre P; Plouin PF; Prodanov T; Quesada-Charneco M; Qin N; Rapizzi E; Raymond V; Reisch N; Roncador G; Ruiz-Ferrer M; Schillo F; Stegmann AP; Suarez C; Taschin E; Timmers HJ; Tops CM; Urioste M; Beuschlein F; Pacak K; Mannelli M; Dahia PL; Opocher G; Eisenhofer G; Gimenez-Roqueplo AP; Robledo M
    Clin Cancer Res; 2012 May; 18(10):2828-37. PubMed ID: 22452945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetics and molecular pathogenesis of pheochromocytoma and paraganglioma.
    Galan SR; Kann PH
    Clin Endocrinol (Oxf); 2013 Feb; 78(2):165-75. PubMed ID: 23061808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exosomal double-stranded DNA as a biomarker for the diagnosis and preoperative assessment of pheochromocytoma and paraganglioma.
    Wang L; Li Y; Guan X; Zhao J; Shen L; Liu J
    Mol Cancer; 2018 Aug; 17(1):128. PubMed ID: 30139385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunohistochemical NF1 analysis does not predict NF1 gene mutation status in pheochromocytoma.
    Stenman A; Svahn F; Welander J; Gustavson B; Söderkvist P; Gimm O; Juhlin CC
    Endocr Pathol; 2015 Mar; 26(1):9-14. PubMed ID: 25403449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma.
    Burnichon N; Vescovo L; Amar L; Libé R; de Reynies A; Venisse A; Jouanno E; Laurendeau I; Parfait B; Bertherat J; Plouin PF; Jeunemaitre X; Favier J; Gimenez-Roqueplo AP
    Hum Mol Genet; 2011 Oct; 20(20):3974-85. PubMed ID: 21784903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetics of pheochromocytoma and paraganglioma.
    Wachtel H; Fishbein L
    Curr Opin Endocrinol Diabetes Obes; 2021 Jun; 28(3):283-290. PubMed ID: 33764930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemical expression of stem cell markers in pheochromocytomas/paragangliomas is associated with SDHx mutations.
    Oudijk L; Neuhofer CM; Lichtenauer UD; Papathomas TG; Korpershoek E; Stoop H; Oosterhuis JW; Smid M; Restuccia DF; Robledo M; de Cubas AA; Mannelli M; Gimenez-Roqueplo AP; Dinjens WN; Beuschlein F; de Krijger RR
    Eur J Endocrinol; 2015 Jul; 173(1):43-52. PubMed ID: 25916394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeted Exome Sequencing of Krebs Cycle Genes Reveals Candidate Cancer-Predisposing Mutations in Pheochromocytomas and Paragangliomas.
    Remacha L; Comino-Méndez I; Richter S; Contreras L; Currás-Freixes M; Pita G; Letón R; Galarreta A; Torres-Pérez R; Honrado E; Jiménez S; Maestre L; Moran S; Esteller M; Satrústegui J; Eisenhofer G; Robledo M; Cascón A
    Clin Cancer Res; 2017 Oct; 23(20):6315-6324. PubMed ID: 28720665
    [No Abstract]   [Full Text] [Related]  

  • 32. Leiomyosarcoma with alternative lengthening of telomeres is associated with aggressive histologic features, loss of ATRX expression, and poor clinical outcome.
    Liau JY; Tsai JH; Jeng YM; Lee JC; Hsu HH; Yang CY
    Am J Surg Pathol; 2015 Feb; 39(2):236-44. PubMed ID: 25229770
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas.
    Liau JY; Tsai JH; Yang CY; Lee JC; Liang CW; Hsu HH; Jeng YM
    Hum Pathol; 2015 Sep; 46(9):1360-6. PubMed ID: 26190196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical characteristics of pheochromocytoma patients with germline mutations in SDHD.
    Dannenberg H; van Nederveen FH; Abbou M; Verhofstad AA; Komminoth P; de Krijger RR; Dinjens WN
    J Clin Oncol; 2005 Mar; 23(9):1894-901. PubMed ID: 15774781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequent EPAS1/HIF2α exons 9 and 12 mutations in non-familial pheochromocytoma.
    Welander J; Andreasson A; Brauckhoff M; Bäckdahl M; Larsson C; Gimm O; Söderkvist P
    Endocr Relat Cancer; 2014 Jun; 21(3):495-504. PubMed ID: 24741025
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HRAS mutation prevalence and associated expression patterns in pheochromocytoma.
    Stenman A; Welander J; Gustavsson I; Brunaud L; Bäckdahl M; Söderkvist P; Gimm O; Juhlin CC; Larsson C
    Genes Chromosomes Cancer; 2016 May; 55(5):452-9. PubMed ID: 26773571
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic Mutation of the Succinate Dehydrogenase C Promoter in a Patient With Two Paragangliomas.
    Richter S; Klink B; Nacke B; de Cubas AA; Mangelis A; Rapizzi E; Meinhardt M; Skondra C; Mannelli M; Robledo M; Menschikowski M; Eisenhofer G
    J Clin Endocrinol Metab; 2016 Feb; 101(2):359-63. PubMed ID: 26652933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetics and imaging of pheochromocytomas and paragangliomas: current update.
    Katabathina VS; Rajebi H; Chen M; Restrepo CS; Salman U; Vikram R; Menias CO; Prasad SR
    Abdom Radiol (NY); 2020 Apr; 45(4):928-944. PubMed ID: 31069476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multimodality Radionuclide Imaging in a Patient With Hereditary Paraganglioma-Pheochromocytoma Syndrome.
    Yim SY; Moncayo VM; Pasquel FJ; Halkar RK
    Clin Nucl Med; 2017 Dec; 42(12):964-965. PubMed ID: 28902732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma.
    Gimm O; Armanios M; Dziema H; Neumann HP; Eng C
    Cancer Res; 2000 Dec; 60(24):6822-5. PubMed ID: 11156372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.